| Not Yet Recruiting | Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-n Solid Tumor | Phase 2 | 2026-09-01 |
| Not Yet Recruiting | Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. Breast Cancer | Phase 2 | 2026-05-01 |
| Not Yet Recruiting | Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination | Phase 2 | 2026-02-10 |
| Not Yet Recruiting | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 2 | 2025-12-01 |
| Recruiting | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC | Phase 2 | 2025-09-28 |
| Recruiting | The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | 2025-09-26 |
| Recruiting | Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics Malignant Neoplasm, Organ Damage | — | 2025-09-15 |
| Recruiting | Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer Breast Cancer | Phase 2 | 2025-09-12 |
| Not Yet Recruiting | This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Moni HER2-positive Breast Cancer | Phase 2 | 2025-09-01 |
| Recruiting | Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma. Squamous Oesophageal Cancer | Phase 2 | 2025-09-01 |
| Not Yet Recruiting | A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradi Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | Phase 2 | 2025-08-10 |
| Not Yet Recruiting | Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progressio PD-(L)1, CTLA-4, Advanced Melanoma | Phase 4 | 2025-07-01 |
| Recruiting | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Fiel Locally Advanced Rectal Cancer | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebe HER2-positive Breast Cancer | — | 2025-06-30 |
| Recruiting | Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection Neutropenia | — | 2025-06-18 |
| Recruiting | Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer Rectal Cancer Stage I | Phase 2 | 2025-05-15 |
| Recruiting | Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） Colon Cancer | Phase 2 | 2025-05-15 |
| Not Yet Recruiting | Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Patholo Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III | Phase 2 | 2025-04-01 |
| Not Yet Recruiting | Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lu Small Cell Lung Cancer Extensive Stage | Phase 2 | 2025-03-01 |
| Not Yet Recruiting | Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Ce Esophageal Carcinoma | Phase 2 | 2024-11-01 |
| Recruiting | Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer Breast Cancer | — | 2024-09-13 |
| Recruiting | Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2024-08-01 |
| Not Yet Recruiting | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell C Esophageal Squamous Cell Carcinoma | Phase 1 | 2024-06-27 |
| Withdrawn | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcino Esophageal Squamous Cell Carcinoma | N/A | 2024-05-30 |
| Not Yet Recruiting | A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Cancer, Therapy-Related | — | 2024-04-20 |
| Recruiting | Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma Esophageal Neoplasms | Phase 2 | 2024-04-01 |
| Unknown | A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Sta Extensive Stage Small Cell Lung Cancer | — | 2024-03-26 |
| Recruiting | Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cance Rectal Cancer | Phase 2 | 2024-02-01 |
| Recruiting | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treate HER2-positive Breast Cancer, Advanced Breast Cancer | Phase 4 | 2024-01-02 |
| Recruiting | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer Colorectal Cancer | Phase 2 | 2024-01-01 |
| Recruiting | Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Can Breast Cancer | Phase 2 | 2023-09-30 |
| Not Yet Recruiting | A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Rec Epithelial Ovarian Cancer | — | 2023-09-01 |
| Completed | Subanesthetic Esketamine for Hemodynamic Stability and Recovery in Elderly Thoracic Surgery Patients Hemodynamic Instability, Postoperative Recovery, Thoracic Surgery | N/A | 2023-06-01 |
| Recruiting | Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) SCLC, Limited Stage | Phase 2 | 2023-06-01 |
| Unknown | Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | — | 2023-05-22 |
| Recruiting | Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic Lung Adenocarcinoma | N/A | 2023-05-01 |
| Recruiting | Minimally Residual of Esophageal Cancer 001 Esophageal Carcinoma, Minimal Residual Disease | — | 2023-02-22 |
| Recruiting | Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors Trilaciclib, CDK4/6-dependent Solid Tumors | Phase 1 | 2023-01-01 |
| Recruiting | Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer Esophageal Carcinoma | — | 2022-10-01 |
| Unknown | Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Can Solid Tumor | Phase 2 | 2022-09-10 |
| Recruiting | Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 2 | 2022-05-01 |
| Recruiting | Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer Solid Tumor | Phase 4 | 2022-03-31 |
| Completed | Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cance Locally Advanced Rectal Cancer | Phase 2 | 2021-09-01 |
| Unknown | Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer Observational, Prospective | — | 2021-07-01 |
| Recruiting | Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer Breast Cancer, HER2-negative Breast Cancer | — | 2020-11-19 |
| Unknown | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tu Advanced Solid Tumor | Phase 2 | 2020-07-16 |
| Unknown | A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advance Esophageal Cancer | Phase 2 | 2020-04-22 |
| Active Not Recruiting | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab f Breast Cancer | Phase 2 / Phase 3 | 2020-03-01 |
| Recruiting | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Ca Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel | Phase 2 | 2019-11-20 |
| Recruiting | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-ne Triple Negative Breast Cancer, Nab-paclitaxel | Phase 2 | 2019-11-20 |
| Unknown | A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer Stage III Breast Cancer | Phase 2 / Phase 3 | 2019-08-01 |
| Withdrawn | Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC Triple Negative Breast Cancer | N/A | 2019-05-10 |
| Unknown | Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Explora HER2-positive Breast Cancer | Phase 2 | 2019-04-30 |
| Recruiting | Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Phase 2 | 2019-04-24 |
| Unknown | Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma Aspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell Carcinoma | EARLY_Phase 1 | 2019-04-10 |
| Unknown | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squa Esophageal Squamous Cell Carcinoma | Phase 2 | 2019-03-01 |
| Unknown | A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR M NSCLC | N/A | 2018-08-15 |
| Active Not Recruiting | Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（C ESCC | N/A | 2018-01-01 |
| Terminated | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Ce Refractory or Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | 2017-11-01 |
| Unknown | Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer Breast Cancer | Phase 2 / Phase 3 | 2017-06-01 |
| Unknown | Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Pat Breast Cancer Metastatic | Phase 2 | 2016-11-24 |
| Unknown | The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lym Diffuse Large B-cell Lymphoma | N/A | 2016-11-01 |
| Unknown | Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Breast Cancer | Phase 4 | 2016-09-01 |
| Completed | A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer Breast Cancer | N/A | 2015-05-01 |
| Active Not Recruiting | The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO Esophageal Carcinoma | — | 2015-01-01 |
| Completed | Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Bre Breast Cancer | N/A | 2015-01-01 |
| Unknown | Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection Non-small Cell Lung Cancer Stage Ⅱ, Non-small Cell Lung Cancer Stage ⅢA | Phase 2 | 2014-12-01 |
| Recruiting | Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Esophageal Neoplasm | — | 2000-01-01 |